Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TACE-HAIC + TKI + PD-1 inhibitor
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Intra-arterial
01
Overview
This combination regimen, studied by Yunfei Yuan at Sun Yat-Sen University Cancer Center, integrates locoregional and systemic therapies for the treatment of advanced hepatocellular carcinoma (HCC), particularly in patients with portal vein tumor thrombus (PVTT). The regimen consists of Transcatheter Arterial Chemoembolization (TACE) and Hepatic Artery Infusion Chemotherapy (HAIC) using agents such as oxaliplatin, 5-fluorouracil, and epirubicin, combined with systemic Tyrosine Kinase Inhibitors (TKIs) like lenvatinib, sorafenib, or apatinib, and PD-1 inhibitors such as camrelizumab or sintilimab. This triple-therapy approach aims to maximize local tumor control while simultaneously addressing systemic disease and enhancing the anti-tumor immune response, showing significant improvements in overall survival and response rates in clinical studies.
- Other names
- TACE-HAIC combined with TKIs and PD-1 inhibitorsTriple combination therapy for HCCTACE-HAIC + Targeted Therapy + Immunotherapy
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)DNATS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on TACE-HAIC + TKI + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TACE-HAIC + TKI + PD-1 inhibitor.